COLUMN: Nipah 2026 — Why Kerala Still Has No Vaccine After Six Outbreaks in Eight Years

COLUMN: Nipah 2026 — Why Kerala Still Has No Vaccine After Six Outbreaks in Eight Years

Introduction: The Return of the Ghost Virus

Kozhikode, again — the patient on a ventilator

On June 23, 2026, The Hindu reported that a patient from the district of Kozhikode, in the Indian state of Kerala, had been on ventilator support since June 10 at the Government Medical College Hospital. The source of the Nipah virus infection remained undetermined despite intensive investigation. Of the 93 close contacts identified and placed under surveillance, all were testing negative as of June 23. The health department stated that the outbreak had been brought under control. 93 contacts monitored. Zero confirmed transmissions. One patient on a ventilator. That is the provisional balance — official relief, persistent scientific unease.

What does not change, from one outbreak to the next, is the absence of a decisive therapeutic tool. In 2018, Kerala's first major Nipah outbreak: no vaccine. In 2021, the virus returned: no vaccine. In 2023: no vaccine. In 2026: no vaccine. The World Health Organization (WHO) placed the Nipah virus on its Research and Development priority list back in 2018 — alongside Ebola, Zika, and Covid-19. Eight years later, that classification remains a strategic intention that has not translated into a clinically approved product. That is the story this piece tells — and frankly, it is one of the most foreseeable and least excusable failures in contemporary global medicine.

The mortality rate that chills

For context: the Nipah virus has an estimated fatality rate of between 40% and 75% depending on the outbreak, with some specialist analyses citing ranges up to 90% in specific flare-ups. By comparison, SARS-CoV-2 (Covid-19) had a globally lower fatality rate of under 2% for the general population — and generated a global vaccine response in under a year. Nipah kills between 40 and 75 people out of every 100 infected — and we still have no approved vaccine after twenty-five years of known pathogen. If that does not outrage you, you have not truly stopped to read those figures.

Fruit bats (Pteropus) are recognized as the primary reservoir of the virus. Transmission to humans occurs through contact with infected animals, contaminated fruit or palm sap, and then through close human-to-human spread. Samples collected in June 2026 within a 5 km radius of the Kozhikode patient's home — dead bats, bird droppings, bodily fluids from domestic animals — had all returned negative. The National Institute of High Security Animal Diseases in Bhopal received the specimens for deeper analysis. The precise origin of the contamination remains unknown.

The History of Outbreaks — An Infernal Cycle

1999–2026: twenty-seven years of recurrence without a solution

The Nipah virus was first identified in 1999 in Malaysia, during an outbreak that killed 105 people and required the culling of more than a million pigs. Since then, the virus has resurfaced sporadically — mainly in Bangladesh and India, with near-annual cycles in Bangladesh and recurring outbreaks in Kerala. In Kerala alone, the virus has struck in 2018 (17 deaths), 2021, 2023, and again in 2026. Six outbreaks in less than ten years in this single region — and every time the same disarming finding: no approved vaccine, no effective specific treatment.

The pattern is depressingly predictable. An alert is raised, contacts are identified and monitored, isolation measures are applied, the outbreak is contained through the efforts of public health teams — dedicated professionals working in difficult conditions with insufficient protective equipment. Then the alert is lifted, the world moves on, and Nipah research funding drops back to its usual, insufficient level. Until the next time. This cycle is not inevitable — it is a collective choice that our societies have not yet decided to reverse.

Why Kerala is particularly exposed

The recurring outbreaks in Kerala are explained by several converging factors. The state is densely forested, with close coexistence between human populations and fruit bat colonies. The tradition of consuming raw palm sap — contaminated by bat droppings — creates regular transmission pathways. The agricultural sector exposes many people to potentially contaminated produce. High population density facilitates human-to-human transmission once the virus enters the human chain. And the state's proximity to other regions of South and Southeast Asia where viral reservoirs are present maintains constant pressure.

The painful irony is that Kerala has one of the strongest public health systems in India — with infant mortality, life expectancy and vaccination coverage indicators comparable to those of far wealthier countries. It is precisely thanks to this institutional solidity that every Nipah outbreak has been contained. Without it, the death tolls would have been catastrophic. But a strong public health system cannot indefinitely substitute for the absence of a vaccine. That is not a solution — it is crisis management.

The Science Exists — Why Not the Vaccine?

The promising candidates that have not yet delivered

Research on a Nipah virus vaccine is not at zero — it is simply inadequately funded and supported. In November 2024, a team at the Vaccine Research Institute (Inserm, Paris) presented promising results for a candidate vaccine called CD40.NiV, which targets certain parts of the virus's surface proteins. Tested in preclinical animal studies, this vaccine demonstrated good immunogenicity (the ability to induce an immune response) and complete protection against disease, as well as potential protection against transmission. This is a genuine advance — but it is still far from the Phase III clinical trials required for regulatory approval.

Other programs exist. mRNA technology, whose development speed was proven during the Covid-19 pandemic, is theoretically applicable to the Nipah virus. Teams at Moderna and BioNTech have explored pathways. The Coalition for Epidemic Preparedness Innovations (CEPI), founded specifically to fund research on "orphan" pathogens with high epidemic potential, has identified Nipah as a priority target. Several vaccine candidates are in early clinical trial phases. The problem is not scientific — the science knows how to proceed. The problem is one of funding and prioritization.

The economic calculation that kills

The central challenge is brutal to state but impossible to sidestep: developing a vaccine costs between $500 million and several billion dollars, depending on the trials required. For a pathogen that generates outbreaks affecting at most a few hundred people at a time, in low-income regions, no traditional pharmaceutical company can justify that investment on commercial return alone. The market says no. And since we have chosen to entrust a significant portion of our vaccine infrastructure to the private sector, the market wins.

CEPI, the American BARDA, funding from the Bill and Melinda Gates Foundation, the COVAX mechanism — all of these instruments were created precisely to correct this market failure. But their funding capacity remains vastly smaller than the real need. And above all: as long as a Nipah outbreak is "managed" by public health systems without triggering a global pandemic, the political pressure to mobilize resources commensurate with the risk remains low. We wait for the catastrophe before acting — and with Nipah, that strategy is particularly dangerous.

The Public Health Response — Between Excellence and Exhaustion

Frontline teams: heroes without a safety net

Each Nipah outbreak in Kerala mobilizes public health teams — physicians, nurses, epidemiologists, field workers — who do remarkable work under difficult conditions. Identifying and monitoring 93 contacts in a matter of days, daily surveillance, managing sample collection and transport to specialist laboratories — all of this requires rigorous organization and considerable personal commitment. The healthcare workers who treat a Nipah patient take a real risk, even with adequate protective equipment.

These health professionals deserve more than public gratitude. They deserve a vaccine that would allow them to do their work without risking their lives. They deserve effective therapeutic protocols for the patients in their care, not just supportive care and symptom management. And they deserve to have their expertise — accumulated outbreak by outbreak — integrated into global research programs on the virus. That is not the case today, or not sufficiently so. The global scientific hierarchy has not yet learned to listen to those who live the problem from the inside.

The containment strategy: effective but precarious

In the absence of a vaccine, the containment strategy — rapid case identification, strict isolation, contact tracing, intensive surveillance — has proven its effectiveness in Kerala. Every outbreak has been contained before becoming an extended transmission chain. That is a major public health achievement. But this strategy has limits: it depends on very early detection of the first case, a responsive laboratory infrastructure, sufficient isolation capacity, and a cooperative population. It can fail if any of these elements breaks down — or if the virus evolves toward higher transmissibility.

The WHO does not recommend travel restrictions to affected zones during Nipah outbreaks, recognizing that local containment measures are generally sufficient. But this recommendation rests on an assumption of limited virus transmissibility. It could change rapidly if Nipah's epidemiological profile shifted. The absence of an available vaccine in that scenario would represent a global health emergency of a magnitude comparable to the Covid-19 pandemic — but with a potentially far higher fatality rate.

The WHO and Priority Disease Policy: Between Intention and Reality

Nipah on the list — since 2018

Since 2018, the Nipah virus has featured on the WHO's list of priority pathogens for emergency research and development — alongside Ebola, Zika, MERS, SARS and other pathogens with high epidemic potential. This classification is meant to trigger a mobilization of resources to accelerate the development of medical countermeasures — vaccines, treatments, diagnostics. It signals to the scientific community and to funders that the risk is recognized and considered serious enough to warrant a collective effort.

In practice, this listing has had effects — but insufficient ones. Nipah research funding has increased, programs are active, vaccine candidates are advancing through early clinical phases. But there is still, in June 2026, no vaccine approved for human use. Eight years after the WHO classification. Six outbreaks in Kerala. A patient on a ventilator in Kozhikode. The WHO priority list is a starting signal — not a guarantee of arrival. And the arrival, in terms of a Nipah vaccine, is long overdue.

The unlearned lessons of Covid-19

The Covid-19 pandemic demonstrated something important: when political will and funding are aligned, science can produce effective vaccines in record time. The Pfizer-BioNTech and Moderna mRNA vaccines were developed, tested, approved and produced at scale in under a year — an unprecedented performance in medical history. This was possible because the threat was global, it affected wealthy countries, and billions of dollars in public funding were mobilized to eliminate the financial risk that normally paralyzes this kind of development.

Why does that same logic not apply to Nipah? The answer is uncomfortable but honest: because Nipah does not (yet) significantly affect wealthy countries. The political mechanism that triggers large-scale resource mobilization — direct threat to the populations and economies of the states that control funding decisions — is not activated for a disease that kills people in Kerala and Bangladesh. This is a form of health apartheid that our international health governance systems have not yet managed to correct.

Toward a Solution: What Would Need to Happen

Preventive investment, not reactive response

The logic of pandemic preparedness is simple and well-documented: investing $1 in prevention before a pandemic saves between $25 and $100 in response once the pandemic is declared. Covid-19 cost the global economy tens of trillions of dollars — for a disease with a relatively low fatality rate. A Nipah pandemic with its 40 to 75% fatality rate would represent an infinitely greater cost. The cost of developing an approved Nipah vaccine is estimated at a few hundred million to a few billion dollars. The ROI of that investment, in terms of preventing catastrophic risk, is astronomically favorable.

What would be needed concretely: an advance market commitment for a Nipah vaccine, similar to what was set up for pneumococcal vaccines in poor countries, guaranteeing manufacturers a return on investment if their vaccine is approved and adopted. A state-funded accelerated clinical trial program with the emergency regulatory approval mechanisms put in place post-Covid. And integration of Kerala and Bangladesh communities into the design of clinical trials — not only as target populations but as actors in the research.

The actors who could change the equation

Several actors have the capacity to accelerate this trajectory. CEPI, whose mandate is precisely to fund research on "orphan" pathogens, already has an active Nipah program — but one that is underfunded. The governments of the United States, United Kingdom, Germany and the European Union, which have demonstrated their ability to mobilize considerable funding for defence and for Covid, could align their global public health priorities with their rhetoric on international health security. The Bill and Melinda Gates Foundation has a track record of investing in vaccines for low-income countries — Nipah would be a natural candidate.

The Indian government itself — whose state of Kerala suffers the direct consequences — has an obvious interest in pushing for accelerated development. India has a significant pharmaceutical and vaccine industry — the Serum Institute of India, the world's largest vaccine producer, has demonstrated its mass production capacity. The equation is not insurmountable. What is missing is the coordinated political will to trigger it. Every new outbreak in Kerala is an opportunity to make that choice — and so far, every opportunity has been missed.

International Cooperation: The Poorly Learned Lessons of Covid

From COVAX to CEPI: equitable sharing mechanisms still insufficient

The COVAX mechanism — the global platform for equitable Covid-19 vaccine distribution — was presented as a revolution in international solidarity. In practice, wealthy countries pre-ordered doses far beyond their needs, leaving low-income countries waiting additional months. This experience has fed a legitimate mistrust among Global South countries toward promises of equitable sharing. For Nipah, which strikes primarily in South Asia and potentially sub-Saharan Africa, repeating that pattern would be not only unjust but strategically foolish — pandemics do not respect inequalities of vaccine access.

The Coalition for Epidemic Preparedness Innovations (CEPI), founded in 2017 after the Ebola outbreak, has had Nipah on its priority list since 2019 and funds vaccine candidates in development. CEPI's total budget for its current programs is approximately $2 billion over five years — a sum that sounds substantial but represents a fraction of what wealthy countries spent on Covid vaccines. The scale of commitments must be proportional to the scale of potential threats. We are not there yet.

Early warning: surveillance systems still too fragmented

Detecting a Nipah outbreak before it becomes an international epidemic requires a dense, reliable and fast epidemiological surveillance network in at-risk zones — Bangladesh, India, Malaysia, the Philippines. The World Health Organization coordinates the Global Outbreak Alert and Response Network (GOARN), but this network depends on the cooperation and transparency of national governments. The example of China at the start of the Covid-19 pandemic illustrated the limits of a system that relies on the good faith of concerned states.

Researchers at Imperial College London and the Wellcome Sanger Institute are working on genomic surveillance systems capable of detecting the emergence of new variants of zoonotic viruses before they spread to humans. These promising technologies exist — they require stable long-term funding and solid partnerships with at-risk countries. Every investment in this preventive surveillance is insurance against the next pandemic — and insurance whose premium is infinitely smaller than the cost of an unanticipated global crisis.

Kerala on the Front Line: A Health System Under Permanent Pressure

The exemplary response of an Indian state facing recurring adversity

Kerala is frequently cited as a model of epidemic response in international public health circles. Its success rests on a rare combination: a high population literacy rate (96%), a dense network of primary health centers in rural areas, solid local medical team training in managing high-fatality diseases, and an institutional culture of transparency that allows rapid communication with the population without triggering uncontrollable panic. These strengths are real and documented by the scientific publications that have studied the 2018 and 2023 Nipah outbreaks in Kerala.

But this local excellence reaches its limits when confronted with repeated outbreaks. The public health teams managing village lockdowns, the epidemiological contact-tracing investigations and care for isolated patients are working under growing pressure. Medical personnel in the affected districts — Kozhikode, Malappuram — are showing signs of professional burnout linked to the recurrence of alerts. Institutional excellence does not indefinitely compensate for the absence of a vaccine that would break the cycle of these repeated crises.

Cooperation between Indian researchers and international institutions

The National Institute of Virology in Pune, the Wellcome Trust Research Laboratory in Vellore and the Institut Pasteur in Paris are actively collaborating on Nipah research programs. Scientific publications on this virus have increased by 300% since 2018, reflecting growing awareness in the scientific community. Genomic sequence databases for circulating strains are kept up to date. Biosafety protocols at BSL-4 level are applied in laboratories working with the live virus.

These collaborations are valuable but insufficient if not coupled with industrial investments to clear the clinical development milestones of vaccine candidates. The Phase 2 clinical trials of an mRNA vaccine against Nipah developed by Moderna in partnership with CEPI were scheduled for late 2025 — but their progress remains dependent on available funding and conditions of access to at-risk populations. Every month of delay in that program is a month during which a new outbreak could occur, with potentially hundreds of lives at stake.

Conclusion: The Next Outbreak Is Already Scheduled

Next summer, and the summer after that

If the cycle of the past eight years holds, Kerala will likely face another Nipah alert within the next twelve to eighteen months. Fruit bats carry the virus in their population without dying from it — they constitute a permanent reservoir in the region. The species contacts that enable transmissions are structurally present. And without a vaccine to protect at-risk populations — farm workers, health workers, family members of patients — the cycle will repeat. This is not alarmist prediction: it is the linear extrapolation of an observed trend.

The difference between this recurring cycle and a global catastrophe rests on a single factor: the transmissibility of the virus. Today, Nipah spreads poorly from human to human — which is why outbreaks remain localized. If that characteristic were to change, even partially, the absence of an approved vaccine would become a planetary emergency within weeks. We have the science, we have the tools, we have the lessons of Covid-19. What is missing is the political decision not to wait for catastrophe before acting.

The patient in Kozhikode deserves better

The patient currently on a ventilator at the Government Medical College Hospital in Kozhikode is not a statistic. He is a person with a family, a history, a life. He represents, in his medical solitude, the collective failure of an international community that has had twenty-seven years to develop a vaccine against the virus that is keeping him on ventilator support — and has not done so. The disproportion between the weight of global procedures and the medical urgency of one patient is obscene. And it is entirely preventable. That is why this column exists.

Kerala's public health response in 2026 is, once again, exemplary. The frontline teams are dedicated, protocols are followed, surveillance is rigorous. But the exemplary quality of a crisis response should not be used as an excuse for maintaining a structurally failing situation. An approved vaccine would fundamentally change this equation. It is time the world decided to fund it.

Columnist's transparency note

Expertise and limitations

Maxime Marquette is not a virologist, epidemiologist or physician. This column draws on published journalistic and scientific sources, not on personal technical expertise in infectious diseases. Clinical data on the Nipah virus — fatality rates, transmission modes, reservoirs — come from publications by the WHO and recognized scientific organizations. The author acknowledges the possibility that some of his risk estimates may be imprecise — experts themselves do not always agree on Nipah risk scenarios.

The author is convinced that underinvestment in vaccines for diseases primarily affecting poor countries is a real and documented structural injustice. This positioning shapes his tone. He has no ties to pharmaceutical companies, funding bodies or public health institutions. This column was written on June 27, 2026.

Sources and method

This column draws on the The Hindu article of June 23, 2026 covering the Kozhikode outbreak, on epidemiological data published by the WHO concerning the Nipah virus, and on scientific communications by the French Medical Research Foundation (FRM) on the CD40.NiV vaccine candidate. The historical context of Kerala outbreaks comes from journalistic sources and publicly available public health data.

The patient cited in this article is a real person who is the subject of public media coverage. No identifying details beyond those reported in the sources have been added.

By Maxime Marquette, columnist

Sources

Primary sources

The Hindu — Source of infection of Nipah patient in Kozhikode remains unclear — June 23, 2026

French Medical Research Foundation — CD40.NiV vaccine candidate against Nipah — November 2024

Femme Actuelle — Nipah virus in India 2026: symptoms, transmission — January 2026

Secondary sources

TF1 Info — Nipah virus: no vaccine, high mortality — September 2023

Catalane de Presse — Health alert: Nipah virus resurfaces in India — January 2026

Spanish Ministry of Health — Note on the Nipah India 2026 outbreak — January 2026